Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael S. Rafii, MD, PhD

    TitleAssociate Professor of Clinical Neurology
    SchoolKeck School of Medicine of USC
    AddressATR 9860 Mesa Rim Road
    Health Sciences Campus
    San Diego California 92121
    Phone+1 858 964 0638
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Michael Rafii, MD, PhD is Clinical Director of the Alzheimer’s Therapeutic Research Institute (ATRI) and Associate Professor of Clinical Neurology at the Keck School of Medicine of the University of Southern California (USC). He received his MD and PhD degrees from Brown University School of Medicine and conducted neurogenetics research at Harvard Medical School. He holds two patents for protein-based therapeutics from his work as a graduate student. Dr. Rafii completed his residency in Neurology at the Johns Hopkins Hospital where he was chief resident. He then undertook a fellowship in dementia at UC San Diego.

      Dr. Rafii’s research focuses on the design and conduct of multi-center clinical trials for Alzheimer's disease, including Alzheimer’s in individuals with Down syndrome. He is ad hoc member of the NIH study section on Developmental Brain Disorders and co-editor of the textbook 'Common Pathogenic Mechanisms between Down Syndrome and Alzheimer's Disease: Steps toward Therapy.' Dr. Rafii previously served as Medical Director of the Alzheimer’s Disease Cooperative Study (ADCS), Director of the Memory Disorders Clinic and Director of the Neurology Residency Training program at UC San Diego.

      Dr. Rafii holds a joint appointment at UC San Diego.

      Collapse Biography 
      Collapse Awards and Honors
      LuMind Down Syndrome Research Foundation2016David Cox Award
      The Johns Hopkins Hospital2006Preziosi Outstanding Neurology Resident Award
      The Johns Hopkins Hospital2006Alpha Omega Alpha
      The Johns Hopkins University/Sinai Hospital2003Intern of the Year
      Brown University School of Medicine2002Aronson Prize for Excellence in Neuroscience

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, d'Ardhuy XL, Capone G, Conners FA, Mervis CB, Abbeduto L, Rafii M, Krinsky-McHale SJ, Urv T, Group OMW. Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017 05; 122(3):247-281. PMID: 28452584.
        View in: PubMed
      2. Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii M, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 Apr 05. PMID: 28381506.
        View in: PubMed
      3. Rafii M, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2017; 60(2):439-450. PMID: 28946567.
        View in: PubMed
      4. Rafii M. Targeting tau protein in Alzheimer's disease. Lancet. 2016 12 10; 388(10062):2842-2844. PMID: 27863808.
        View in: PubMed
      5. Rafii M. Improving Memory and Cognition in Individuals with Down Syndrome. CNS Drugs. 2016 07; 30(7):567-73. PMID: 27272473.
        View in: PubMed
      6. Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii M. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimers Dement (N Y). 2016 Jun; 2(2):69-81. PMID: 28642933.
        View in: PubMed
      7. Rafii M, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. PMID: 26441570; PMCID: PMC4568340.
      8. Rafii M. Active Immunotherapy for Alzheimer's Disease: The Road Ahead. J Prev Alzheimers Dis. 2015 Jun; 2(2):78-79. PMID: 28331846.
        View in: PubMed
      9. Rafii M, Aisen PS. Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. PMID: 25857341; PMCID: PMC4373002.
      10. Rafii M. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome? Alzheimers Res Ther. 2014; 6(5-8):60. PMID: 25478025; PMCID: PMC4255529.
      11. Rafii M, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81. PMID: 24411134.
        View in: PubMed
      12. Rafii M. Preclinical Alzheimer's disease therapeutics. J Alzheimers Dis. 2014; 42 Suppl 4:S545-9. PMID: 25079804.
        View in: PubMed
      13. Rafii M, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. PMID: 24164929.
        View in: PubMed
      14. Moran JA, Rafii M, Keller SM, Singh BK, Janicki MP. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013 Aug; 88(8):831-40. PMID: 23849993.
        View in: PubMed
      15. Desikan RS, Rafii M, Brewer JB, Hess CP. An expanded role for neuroimaging in the evaluation of memory impairment. AJNR Am J Neuroradiol. 2013 Nov-Dec; 34(11):2075-82. PMID: 23764728; PMCID: PMC4077712.
      16. Rafii M. Update on Alzheimer's disease therapeutics. Rev Recent Clin Trials. 2013 Jun; 8(2):110-8. PMID: 23859061.
        View in: PubMed
      17. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. PMID: 22935789.
        View in: PubMed
      18. Rafii M, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011 Apr 19; 76(16):1389-94. PMID: 21502597; PMCID: PMC3269774.
      19. Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition. Am J Alzheimers Dis Other Demen. 2011 05; 26(3):235-9. PMID: 21406427; PMCID: PMC3568924.
      20. Rafii M, Brewer JB. Functional brain imaging in the clinical assessment of consciousness. PLoS Biol. 2010 Nov 30; 8(11):e1000548. PMID: 21151340; PMCID: PMC2994656.
      21. Rafii M. The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials. 2010 Jan; 5(1):57-62. PMID: 20205688.
        View in: PubMed
      22. Kovacevic S, Rafii M, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2009 Apr-Jun; 23(2):139-45. PMID: 19474571; PMCID: PMC2688740.
      23. Rafii M, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. PMID: 19228370; PMCID: PMC2649159.
      24. Rafii M, Galasko D. Primary care screening for dementia and mild cognitive impairment. JAMA. 2008 Mar 12; 299(10):1132; author reply 1133-4. PMID: 18334686.
        View in: PubMed
      25. Rafii M, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol. 2006 Nov; 209(2):439-47. PMID: 16883602; PMCID: PMC2929672.
      26. Rafii M. Case 14: a woman with bilateral Bell's palsy. MedGenMed. 2006 Oct 31; 8(4):23. PMID: 17415306; PMCID: PMC1868343.
      27. Rafii M, Hillis AE. Compendium of cerebrovascular diseases. Int Rev Psychiatry. 2006 Oct; 18(5):395-407. PMID: 17085359.
        View in: PubMed
      28. Mercado ML, Amenta AR, Hagiwara H, Rafii M, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. 2006 Aug; 20(10):1724-6. PMID: 16807372; PMCID: PMC3056440.
      29. Rafii M, Koenig M, Ziai WC. Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology. 2005 Dec 27; 65(12):1906. PMID: 16380611.
        View in: PubMed
      30. Moore SL, Rafii M. Imaging of musculoskeletal and spinal tuberculosis. Radiol Clin North Am. 2001 Mar; 39(2):329-42. PMID: 11316362.
        View in: PubMed
      31. Berzin TM, Zipser BD, Rafii M, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr; 21(2):349-55. PMID: 10867220.
        View in: PubMed
      32. Donahue JE, Berzin TM, Rafii M, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG. Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc Natl Acad Sci U S A. 1999 May 25; 96(11):6468-72. PMID: 10339611; PMCID: PMC26905.
      Michael's Networks
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Similar People
      People who share similar concepts with this person.
      Same Department